

**Table S6.** Single markers and their characteristics that have been investigated in more than one study series, however of which Cox regression survival analysis was not available for all markers.

Study	Marker	Endpoint	HR (95% CI)	P	N	Stage	REMARK score
Kandimalla et al. 2017	AXIN2, DKK1	RFS	3.84 (1.14-12.43)		65	II	15
Kandimalla et al. 2017	AXIN2, DKK1	RFS		<0.0004	79	II	15
Aoyagi et al. 2011	CDKN2A, MLH1	OS		0.0318	134	IV	10
Veganzones et al. 2015	CDKN2A, MLH1	DFS	0.028 (0.0-42.1)	0.04	51	I-IV	12
Umetani et al. 2004	ID4	OS	1.82 (1.09-3.43)		76	I-IV	9.5
Tanaka et al. 2011	ID4	OS		0.118	82	II-III	14.5
Shannon et al. 1999	MYOD1 (Myf-3)	NA		0.14	NA	II-III	4.5
Hiranuma et al. 2004	MYOD1	OS	3.16 (1.25-8.02)		80	II-III	9
Tang et al. 2011	SFRP2	OS	3.06 (1.12-8.40)		77	I-IV	10
Yang et al. 2014	SFRP2	Mortality	NA	NA	184	I-IV	10.5

NA = not reported

DFS = Disease-free survival

OS = Overall survival

HR = Hazard ratio Cox regression analysis

P = p-value Kaplan-Meier